Differential MSH2 promoter methylation in blood cells of Neurofibromatosis type 1 (NF1) patients

被引:21
|
作者
Titze, Sabrina [1 ]
Peters, Hartmut [2 ]
Waehrisch, Sandra [1 ]
Harder, Thomas [3 ]
Guse, Katrin [1 ]
Buske, Annegret [2 ]
Tinschert, Sigrid [2 ,4 ]
Harder, Anja [1 ]
机构
[1] Charite, Inst Neuropathol, D-10117 Berlin, Germany
[2] Charite, Inst Med Genet, D-10117 Berlin, Germany
[3] Charite, Clin Obstet, Res Grp Expt Obstet, D-10117 Berlin, Germany
[4] Tech Univ Dresden, Inst Clin Genet, Med Fac Carl Gustav Carus, Dresden, Germany
关键词
neurofibromatosis type 1; NF1; mismatch repair; MSH2; neurofibroma; methylation; modifier; SCHWANN-CELLS; HIGH-FREQUENCY; HMLH1; GENE; MUTATION; HYPERMETHYLATION; EXPRESSION; CANCER; HMSH2; IDENTIFICATION; DEFECTS;
D O I
10.1038/ejhg.2009.129
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neurofibromatosis type 1 (NF1) is caused by NF1 gene mutations. The phenotype is highly variable, with 'modifiers' being discussed as potential determinants. Mismatch repair deficiency was shown to cause NF1 mutations, but constitutional mutation of mismatch repair genes was identified only once in a NF1 patient. We aimed to analyze whether DNA methylation of mismatch repair gene promoters, known to lead to transcriptional silencing, is associated with increased tumor load in NF1 defined by the number of cutaneous neurofibromas. Leukocyte DNA of 79 controls and 79 NF1 patients was investigated for methylation of mismatch repair genes MLH1, MSH2, MSH6, and PMS2 by methylation-specific PCR and pyrosequencing. MLH1, MSH6, and PMS2 promoters were not methylated. By contrast, we found promoter methylation of MSH2 with a higher rate of methylation in NF1 patients compared with controls. Furthermore, when comparing NF1 patients with a low vs those with a high number of cutaneous neurofibromas, MSH2 promoter methylation was significantly different. In patients with a high tumor burden, methylation of two (out of six) CpGs was enhanced. This finding was not confounded by age. In conclusion, enhanced methylation involving transcription start points of mismatch repair genes, such as MSH2 in NF1, has not been described so far. Methylation-induced variability of MSH2 gene expression may lead to variable mismatch repair capacity. Our results may point toward a role of MSH2 as a modifier for NF1, although the amount of DNA methylation and subsequent gene expression in other cell types of NF1 patients needs to be elucidated. European Journal of Human Genetics (2010) 18, 81-87; doi:10.1038/ejhg.2009.129; published online 29 July 2009
引用
收藏
页码:81 / 87
页数:7
相关论文
共 50 条
  • [1] Differential MSH2 promoter methylation in blood cells of Neurofibromatosis type 1 (NF1) patients
    Sabrina Titze
    Hartmut Peters
    Sandra Währisch
    Thomas Harder
    Katrin Guse
    Annegret Buske
    Sigrid Tinschert
    Anja Harder
    European Journal of Human Genetics, 2010, 18 : 81 - 87
  • [2] Monozygotic Twins With Neurofibromatosis Type 1 (NF1) Display Differences in Methylation of NF1 Gene Promoter Elements, 5′ Untranslated region, Exon and Intron 1
    Harder, Anja
    Titze, Sabrina
    Herbst, Lena
    Harder, Thomas
    Guse, Katrin
    Tinschert, Sigrid
    Kaufmann, Dieter
    Rosenbaum, Thorsten
    Mautner, Victor Felix
    Windt, Elke
    Wahllaender-Danek, Ute
    Wimmer, Katharina
    Mundlos, Stefan
    Peters, Hartmut
    TWIN RESEARCH AND HUMAN GENETICS, 2010, 13 (06) : 582 - 594
  • [3] Lymphomas in patients with neurofibromatosis type 1 (NF1): another malignancy in the NF1 syndrome?
    Fareez, Faiha
    Wang, Bill H.
    Brain, Ian
    Lu, Jian-Qiang
    PATHOLOGY, 2023, 55 (03) : 302 - 314
  • [4] No aberrant methylation of neurofibromatosis 1 gene (NF1) promoter in pilocytic astrocytoma in childhood
    Ebinger, M
    Senf, L
    Wachowski, O
    Scheurlen, W
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2005, 22 (01) : 83 - 87
  • [5] The spectrum of NF1 mutations in Korean patients with neurofibromatosis type 1
    Jeong, SY
    Park, SJ
    Kim, HJ
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2006, 21 (01) : 107 - 112
  • [6] Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq
    Koster, R.
    Brandao, R. D.
    Tserpelis, D.
    van Roozendaal, C. E. P.
    van Oosterhoud, C. N.
    Claes, K. B. M.
    Paulussen, A. D. C.
    Sinnema, M.
    Vreeburg, M.
    van der Schoot, V
    Stumpel, C. T. R. M.
    Broen, M. P. G.
    Spruijt, L.
    Jongmans, M. C. J.
    Oberstein, S. A. J. Lesnik
    Plomp, A. S.
    Misra-Isrie, M.
    Duijkers, F. A.
    Louwers, M. J.
    Szklarczyk, R.
    Derks, K. W. J.
    Brunner, H. G.
    van den Wijngaard, A.
    van Geel, M.
    Blok, M. J.
    NPJ GENOMIC MEDICINE, 2021, 6 (01)
  • [7] Characterization of NF1 frameshift mutations in pediatric patients with neurofibromatosis type I
    Villa-Morales, J.
    Lopez-Munoz, E.
    Juarez-Melchor, D.
    Garcia-Hernandez, N.
    Minauro-Sanmiguel, F.
    Aguirre-Hernandez, J.
    Gutierrez-Iglesias, G.
    Arenas-Aranda, D. J.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (03): : 8326 - 8337
  • [8] Mutation Spectrum of NF1 and Clinical Characteristics in 78 Korean Patients With Neurofibromatosis Type 1
    Ko, Jung Min
    Sohn, Young Bae
    Jeong, Seon Yong
    Kim, Hyon-Ju
    Messiaen, Ludwine M.
    PEDIATRIC NEUROLOGY, 2013, 48 (06) : 447 - 453
  • [9] Clinical and molecular characteristics of thirty NF1 variants in Chinese patients with neurofibromatosis type 1
    Wang, Wen
    Qin, Weibing
    Ge, Hongsong
    Kong, Xiangsheng
    Xie, Chao
    Tang, Yunge
    Li, Ming
    MOLECULAR BIOLOGY REPORTS, 2019, 46 (04) : 4349 - 4359
  • [10] Neurofibromatosis type I: mutation spectrum of NF1 in spanish patients
    Palma Milla, Carmen
    Lezana Rosales, Jose Miguel
    Lopez Montiel, Javier
    Andres Garrido, Lucas David
    Sanchez Linares, Carlos
    Carmona Tamajon, Sandra
    Torres Fernandez, Carmen
    Sanchez Gonzalez, Pablo
    Franco Freire, Sara
    Benito Lopez, Carmen
    Lopez Siles, Juan
    ANNALS OF HUMAN GENETICS, 2018, 82 (06) : 425 - 436